Variable | Patients (n = 32) |
---|---|
Mean Age of onset, year | 33.28 (15–62) |
Sex (n%) | |
 Female | 30 (93.75%) |
 Male | 2 (6.25%) |
Mean BMI | 24.17 (17.57–31.65) |
Mean Disease duration, months | 85.56 (19–266) |
Mean Duration of AZA therapy, months | 21.50 (12–40) |
Clinical symptoms at onset (n%) | |
 Optic neuritis | 21 (65.6%) |
 Bilateral Optic neuritis | 17 (53.13%) |
 Myelitis | 29 (90.6%) |
 Optic neuritis and Myelitis | 19 (59.3%) |
Mean Pre-therapy EDSS score | 5.21 ± 0.24 (2.5–8) |
Mean Post- therapy EDSS score | 2.57 ± 0.33 (0–7) |
Mean Concentration of CSF protein, mg/dl | 40.41 ± 32.67 (12–184) |
Mean Concentration of CSF IgG, mg/ml | 0.04 ± 0.03 (0.01–0.19) |
CSF IgG index (n%) | 0.53 ± 0.10 (0.39–0.83) |
Serum anti-AQP4 antibodies (n%) | 14 (43.75%) |
Mean Concentration of 6-TGNs, pmol/8 × 108 RBC | 202.03 |
Mean Concentration of MMPNs, pmol/8 × 108 RBC | 1618.90 |
Relapse, n% | 12/32 (37.5%) |
Pre- therapy ARR | 1.42 ± 0.23 (0.2–3.5) |
Post- therapy ARR | 0.36 ± 0.09 (0–1.72) |